Outcome of the HORIZONS-AMI trial: Bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 115-123

  Shah, Ashish ^a   Feldman, Dmitriy N ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Antithrombotic; Bivalirudin; PCI; ST elevation myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; TICLOPIDINE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

BARE METAL STENT; BLEEDING; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HEART INFARCTION; MORTALITY; RECURRENT DISEASE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ANTITHROMBINS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863184396     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S23491     Document Type: Review

References (35)

1. WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Committee. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Roe MT, Parsons LS, Pollack CV Jr, et al. National Registry of Myocardial Infarction Investigators. Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med. 2005;165:1630-1636.
3. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205-2241.
4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
5. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med. 1996;334:1084-1089.
6. Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother. 2002;36:1028-1041.
7. White CM. Thrombin-directed inhibitors: pharmacology and clinical use. Am Heart J. 2005;149:S54-S60.
8. Morrow DA. Antithrombotic therapy to support primary PCI. N Engl J Med. 2008;358:2280-2282.
9. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555-1562.
10. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
11. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556-2566.
12. Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation. 2008;118:2139-2145.
13. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813-818.
14. Kadakia MB, Desai NR, Alexander KP, et al; National Cardiovascular Data Registry. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry - GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry - Get With the Guidelines). JACC Cardiovasc Interv. 2010;3:1166-1177.
15. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl): 64S-94S.
16. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293: 1759-1765.
17. Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation. 2003;107:1497-1501.
18. Montalescot G, Barragan P, Wittenberg O, et al. ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
19. van't Hof AW, Ernst N, de Boer MJ, et al; for the On-TIME Study Group. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J. 2004;25:837-846.
20. Zeymer U, Zahn R, Schiele R, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J. 2005;26:1971-1977.
21. Stone GW, Grines CL, Cox DA, et al; for the CADILLAC investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
22. Tcheng JE, Kandzari DE, Grines CL, et al. CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003;108:1316-1323.
23. Gibson CM, Morrow DA, Murphy SA, et al; TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47:2364-2373.
24. Lincoff AM, Bittl JA, Harrington RA, et al; for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
25. Stone GW, McLaurin BT, Cox DA, et al; for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.
26. Stone GW, Witzenbichler B, Guagliumi G, et al; for the HORIZONSAMI Trial Investigators. Bivalirudin during Primary PCI in Acute Myocardial Infarction. N Engl J Med. 2008;358:2218-2230.
27. Mehran R, Brodie B, Cox DA, et al. The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J. 2008;156:44-56.
28. Mehran R, Lansky AJ, Witzenbichler B, et al. HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-1159.
29. Webster MW. HORIZONS-AMI. Lancet. 2010;375:375.
30. Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus baremetal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-2204.
31. Witzenbichler B, Mehran R, Guagliumi G, et al. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty. JACC Cardiovasc Interv. 2011;4:760-768.
32. Parodi G, Antoniucci D, Nikolsky E, et al. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010;3:796-802.
33. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with st-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4:1011-1019.
34. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J. 2008;29:2909-2945.
35. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2007 Focused Update of the 2004 ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2007;51: 210-247.